Issue Date: June 26, 2017
Merck KGaA spins off immuno-oncology firm
Merck KGaA’s corporate venture arm has created a new company, iOnctura, based on two potential drugs from its health care R&D portfolio and three from Cancer Research Technology, the commercial arm of the nonprofit Cancer Research UK. Catherine Pickering, CEO and cofounder of iOnctura, says the firm’s goal is to modulate immunosuppression in the tumor microenvironment to maximize the potential of checkpoint inhibitor drugs. The firm has access to supplies of avelumab, a checkpoint inhibitor being developed by Merck and Pfizer.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society